Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder

L. Fredrik Jarskog, Robert M. Hamer, Diane J. Catellier, Dawn D. Stewart, Lisa LaVange, Neepa Ray, Lauren H. Golden, Jeffrey A. Lieberman, T. Scott Stroup, Lawrence Adler, Glen Burnie, Michael Barber, Matthew Byerly, Jose M. Canive, Ira Glick, David C. Henderson, J. Steven Lamberti, Ahsan Khan, Joseph Patrick McEvoy, Herbert Meltzer & 6 others Alexander Miller, Del D. Miller, Henry A. Nasrallah, Stephen Olson, Jayendra K. Patel, Bruce L. Saltz

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Objective: The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder. Method: In a double-blind study, 148 clinically stable, overweight (body mass index [BMI] ≥27) outpatients with chronic schizophrenia or schizoaffective disorder were randomly assigned to receive 16 weeks of metformin or placebo. Metformin was titrated up to 1,000 mg twice daily, as tolerated. All patients continued to receive their prestudy medications, and all received weekly diet and exercise counseling. The primary outcome measure was change in body weight from baseline to week 16. Results: Fifty-eight (77.3%) patients who received metformin and 58 (81.7%) who received placebo completed 16 weeks of treatment. Mean change in body weight was 23.0 kg (95% CI=24.0 to 22.0) for the metformin group and 21.0 kg (95% CI= 22.0 to 0.0) for the placebo group, with a between-group difference of 22.0 kg (95% CI=23.4 to 20.6). Metformin also demonstrated a significant between-group advantage for BMI (20.7; 95% CI=21.1 to 20.2), triglyceride level (220.2 mg/dL; 95% CI=239.2 to 21.3), and hemoglobin A1c level (20.07%; 95% CI=20.14 to 20.004). Metformin-associated side effects were mostly gastrointestinal and generally transient, and they rarely led to treatment discontinuation. Conclusions: Metformin was modestly effective in reducing weight and other risk factors for cardiovascular disease in clinically stable, overweight outpatients with chronic schizophrenia or schizoaffective disorder over 16 weeks. A significant timeby- treatment interaction suggests that benefits of metformin may continue to accrue with longer treatment. Metforminmay have an important role in diminishing the adverse consequences of obesity and metabolic impairments in patients with schizophrenia.

Original languageEnglish (US)
Pages (from-to)1032-1040
Number of pages9
JournalAmerican Journal of Psychiatry
Volume170
Issue number9
DOIs
StatePublished - Sep 1 2013

Fingerprint

Metformin
Psychotic Disorders
Weight Loss
Schizophrenia
Outpatients
Body Weight Changes
Placebos
Body Mass Index
Therapeutics
Double-Blind Method
Counseling
Hemoglobins
Triglycerides
Cardiovascular Diseases
Obesity
Outcome Assessment (Health Care)
Exercise
Diet
Weights and Measures

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Jarskog, L. F., Hamer, R. M., Catellier, D. J., Stewart, D. D., LaVange, L., Ray, N., ... Saltz, B. L. (2013). Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. American Journal of Psychiatry, 170(9), 1032-1040. https://doi.org/10.1176/appi.ajp.2013.12010127

Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. / Jarskog, L. Fredrik; Hamer, Robert M.; Catellier, Diane J.; Stewart, Dawn D.; LaVange, Lisa; Ray, Neepa; Golden, Lauren H.; Lieberman, Jeffrey A.; Stroup, T. Scott; Adler, Lawrence; Burnie, Glen; Barber, Michael; Byerly, Matthew; Canive, Jose M.; Glick, Ira; Henderson, David C.; Lamberti, J. Steven; Khan, Ahsan; McEvoy, Joseph Patrick; Meltzer, Herbert; Miller, Alexander; Miller, Del D.; Nasrallah, Henry A.; Olson, Stephen; Patel, Jayendra K.; Saltz, Bruce L.

In: American Journal of Psychiatry, Vol. 170, No. 9, 01.09.2013, p. 1032-1040.

Research output: Contribution to journalArticle

Jarskog, LF, Hamer, RM, Catellier, DJ, Stewart, DD, LaVange, L, Ray, N, Golden, LH, Lieberman, JA, Stroup, TS, Adler, L, Burnie, G, Barber, M, Byerly, M, Canive, JM, Glick, I, Henderson, DC, Lamberti, JS, Khan, A, McEvoy, JP, Meltzer, H, Miller, A, Miller, DD, Nasrallah, HA, Olson, S, Patel, JK & Saltz, BL 2013, 'Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder', American Journal of Psychiatry, vol. 170, no. 9, pp. 1032-1040. https://doi.org/10.1176/appi.ajp.2013.12010127
Jarskog, L. Fredrik ; Hamer, Robert M. ; Catellier, Diane J. ; Stewart, Dawn D. ; LaVange, Lisa ; Ray, Neepa ; Golden, Lauren H. ; Lieberman, Jeffrey A. ; Stroup, T. Scott ; Adler, Lawrence ; Burnie, Glen ; Barber, Michael ; Byerly, Matthew ; Canive, Jose M. ; Glick, Ira ; Henderson, David C. ; Lamberti, J. Steven ; Khan, Ahsan ; McEvoy, Joseph Patrick ; Meltzer, Herbert ; Miller, Alexander ; Miller, Del D. ; Nasrallah, Henry A. ; Olson, Stephen ; Patel, Jayendra K. ; Saltz, Bruce L. / Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. In: American Journal of Psychiatry. 2013 ; Vol. 170, No. 9. pp. 1032-1040.
@article{6ffdb07e5a1947d195a0767959a3863d,
title = "Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder",
abstract = "Objective: The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder. Method: In a double-blind study, 148 clinically stable, overweight (body mass index [BMI] ≥27) outpatients with chronic schizophrenia or schizoaffective disorder were randomly assigned to receive 16 weeks of metformin or placebo. Metformin was titrated up to 1,000 mg twice daily, as tolerated. All patients continued to receive their prestudy medications, and all received weekly diet and exercise counseling. The primary outcome measure was change in body weight from baseline to week 16. Results: Fifty-eight (77.3{\%}) patients who received metformin and 58 (81.7{\%}) who received placebo completed 16 weeks of treatment. Mean change in body weight was 23.0 kg (95{\%} CI=24.0 to 22.0) for the metformin group and 21.0 kg (95{\%} CI= 22.0 to 0.0) for the placebo group, with a between-group difference of 22.0 kg (95{\%} CI=23.4 to 20.6). Metformin also demonstrated a significant between-group advantage for BMI (20.7; 95{\%} CI=21.1 to 20.2), triglyceride level (220.2 mg/dL; 95{\%} CI=239.2 to 21.3), and hemoglobin A1c level (20.07{\%}; 95{\%} CI=20.14 to 20.004). Metformin-associated side effects were mostly gastrointestinal and generally transient, and they rarely led to treatment discontinuation. Conclusions: Metformin was modestly effective in reducing weight and other risk factors for cardiovascular disease in clinically stable, overweight outpatients with chronic schizophrenia or schizoaffective disorder over 16 weeks. A significant timeby- treatment interaction suggests that benefits of metformin may continue to accrue with longer treatment. Metforminmay have an important role in diminishing the adverse consequences of obesity and metabolic impairments in patients with schizophrenia.",
author = "Jarskog, {L. Fredrik} and Hamer, {Robert M.} and Catellier, {Diane J.} and Stewart, {Dawn D.} and Lisa LaVange and Neepa Ray and Golden, {Lauren H.} and Lieberman, {Jeffrey A.} and Stroup, {T. Scott} and Lawrence Adler and Glen Burnie and Michael Barber and Matthew Byerly and Canive, {Jose M.} and Ira Glick and Henderson, {David C.} and Lamberti, {J. Steven} and Ahsan Khan and McEvoy, {Joseph Patrick} and Herbert Meltzer and Alexander Miller and Miller, {Del D.} and Nasrallah, {Henry A.} and Stephen Olson and Patel, {Jayendra K.} and Saltz, {Bruce L.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1176/appi.ajp.2013.12010127",
language = "English (US)",
volume = "170",
pages = "1032--1040",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "9",

}

TY - JOUR

T1 - Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder

AU - Jarskog, L. Fredrik

AU - Hamer, Robert M.

AU - Catellier, Diane J.

AU - Stewart, Dawn D.

AU - LaVange, Lisa

AU - Ray, Neepa

AU - Golden, Lauren H.

AU - Lieberman, Jeffrey A.

AU - Stroup, T. Scott

AU - Adler, Lawrence

AU - Burnie, Glen

AU - Barber, Michael

AU - Byerly, Matthew

AU - Canive, Jose M.

AU - Glick, Ira

AU - Henderson, David C.

AU - Lamberti, J. Steven

AU - Khan, Ahsan

AU - McEvoy, Joseph Patrick

AU - Meltzer, Herbert

AU - Miller, Alexander

AU - Miller, Del D.

AU - Nasrallah, Henry A.

AU - Olson, Stephen

AU - Patel, Jayendra K.

AU - Saltz, Bruce L.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Objective: The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder. Method: In a double-blind study, 148 clinically stable, overweight (body mass index [BMI] ≥27) outpatients with chronic schizophrenia or schizoaffective disorder were randomly assigned to receive 16 weeks of metformin or placebo. Metformin was titrated up to 1,000 mg twice daily, as tolerated. All patients continued to receive their prestudy medications, and all received weekly diet and exercise counseling. The primary outcome measure was change in body weight from baseline to week 16. Results: Fifty-eight (77.3%) patients who received metformin and 58 (81.7%) who received placebo completed 16 weeks of treatment. Mean change in body weight was 23.0 kg (95% CI=24.0 to 22.0) for the metformin group and 21.0 kg (95% CI= 22.0 to 0.0) for the placebo group, with a between-group difference of 22.0 kg (95% CI=23.4 to 20.6). Metformin also demonstrated a significant between-group advantage for BMI (20.7; 95% CI=21.1 to 20.2), triglyceride level (220.2 mg/dL; 95% CI=239.2 to 21.3), and hemoglobin A1c level (20.07%; 95% CI=20.14 to 20.004). Metformin-associated side effects were mostly gastrointestinal and generally transient, and they rarely led to treatment discontinuation. Conclusions: Metformin was modestly effective in reducing weight and other risk factors for cardiovascular disease in clinically stable, overweight outpatients with chronic schizophrenia or schizoaffective disorder over 16 weeks. A significant timeby- treatment interaction suggests that benefits of metformin may continue to accrue with longer treatment. Metforminmay have an important role in diminishing the adverse consequences of obesity and metabolic impairments in patients with schizophrenia.

AB - Objective: The purpose of this study was to determine whether metformin promotes weight loss in overweight outpatients with chronic schizophrenia or schizoaffective disorder. Method: In a double-blind study, 148 clinically stable, overweight (body mass index [BMI] ≥27) outpatients with chronic schizophrenia or schizoaffective disorder were randomly assigned to receive 16 weeks of metformin or placebo. Metformin was titrated up to 1,000 mg twice daily, as tolerated. All patients continued to receive their prestudy medications, and all received weekly diet and exercise counseling. The primary outcome measure was change in body weight from baseline to week 16. Results: Fifty-eight (77.3%) patients who received metformin and 58 (81.7%) who received placebo completed 16 weeks of treatment. Mean change in body weight was 23.0 kg (95% CI=24.0 to 22.0) for the metformin group and 21.0 kg (95% CI= 22.0 to 0.0) for the placebo group, with a between-group difference of 22.0 kg (95% CI=23.4 to 20.6). Metformin also demonstrated a significant between-group advantage for BMI (20.7; 95% CI=21.1 to 20.2), triglyceride level (220.2 mg/dL; 95% CI=239.2 to 21.3), and hemoglobin A1c level (20.07%; 95% CI=20.14 to 20.004). Metformin-associated side effects were mostly gastrointestinal and generally transient, and they rarely led to treatment discontinuation. Conclusions: Metformin was modestly effective in reducing weight and other risk factors for cardiovascular disease in clinically stable, overweight outpatients with chronic schizophrenia or schizoaffective disorder over 16 weeks. A significant timeby- treatment interaction suggests that benefits of metformin may continue to accrue with longer treatment. Metforminmay have an important role in diminishing the adverse consequences of obesity and metabolic impairments in patients with schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=84883728317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883728317&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2013.12010127

DO - 10.1176/appi.ajp.2013.12010127

M3 - Article

VL - 170

SP - 1032

EP - 1040

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 9

ER -